tiprankstipranks
Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
Australian Market
Holding AU:AGN?
Track your performance easily

Argenica Therapeutics Ltd (AGN) Share Price & Analysis

7 Followers

AGN Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

5.95%94.05%
― Other Institutional Investors
94.05% Public Companies and
Individual Investors

AGN FAQ

What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.41 and its highest was AU$0.98 in the past 12 months.
    What is Argenica Therapeutics Ltd’s market cap?
    Currently, no data Available
    When is Argenica Therapeutics Ltd’s upcoming earnings report date?
    Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 04, 2025 which is in 101 days.
      How were Argenica Therapeutics Ltd’s earnings last quarter?
      Argenica Therapeutics Ltd released its earnings results on Aug 21, 2024. The company reported -AU$0.039 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.039.
        Is Argenica Therapeutics Ltd overvalued?
        According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Argenica Therapeutics Ltd pay dividends?
          Argenica Therapeutics Ltd does not currently pay dividends.
          What is Argenica Therapeutics Ltd’s EPS estimate?
          Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Argenica Therapeutics Ltd have?
          Argenica Therapeutics Ltd has 128,092,850 shares outstanding.
            What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
            Argenica Therapeutics Ltd reported an EPS of -AU$0.039 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.22%.
              Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
              Currently, no hedge funds are holding shares in AU:AGN
              ---

              Argenica Therapeutics Ltd Stock Smart Score

              Company Description

              Argenica Therapeutics Ltd

              Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its lead neuroprotective peptide candidate, ARG007 improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
              ---

              AGN Stock 12 Month Forecast

              Average Price Target

              AU$1.15
              ▲(59.72% Upside)
              {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"AU$2","-1":"-AU$1","-0.25":"-AU$0.25","0.5":"AU$0.5","1.25":"AU$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$1.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$1.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$1.15</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,0.7992307692307692,0.8284615384615385,0.8576923076923076,0.8869230769230769,0.9161538461538461,0.9453846153846154,0.9746153846153846,1.0038461538461538,1.033076923076923,1.0623076923076922,1.0915384615384616,1.1207692307692307,{"y":1.15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,0.7992307692307692,0.8284615384615385,0.8576923076923076,0.8869230769230769,0.9161538461538461,0.9453846153846154,0.9746153846153846,1.0038461538461538,1.033076923076923,1.0623076923076922,1.0915384615384616,1.1207692307692307,{"y":1.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.77,0.7992307692307692,0.8284615384615385,0.8576923076923076,0.8869230769230769,0.9161538461538461,0.9453846153846154,0.9746153846153846,1.0038461538461538,1.033076923076923,1.0623076923076922,1.0915384615384616,1.1207692307692307,{"y":1.15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.45,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.52,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.56,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.63,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.64,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.58,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.77,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.76,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.86,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.82,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.82,"date":1726185600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
              Similar Stocks
              Company
              Price & Change
              Follow
              LBT Innovations Limited
              PYC Therapeutics Limited
              Little Green Pharma Ltd.

              Best Analysts Covering AGN

              1 Year
              Tanushree JainPetra Capital
              1 Year Success Rate
              0/3 ratings generated profit
              0%
              1 Year Average Return
              -7.07%
              reiterated a buy rating 20 days ago
              Copying Tanushree Jain's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -7.07% per trade.
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis